Evidence map›Paper›PMID 36037521›Full record

ArticleThe international journal of neuropsychopharmacology2022

Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting.

Elizabeth Deckler, Melissa Ferland, Stephanie Brazis, Megan R Mayer, Marlene Carlson, Joshua T Kantrowitz

Abstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Serotonin type 3 receptor (5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Increasing participation of people with thought disorder in clinical research.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elizabeth DecklerJackson Memorial Hospital, Miami, Florida, USA.
Melissa FerlandNew York State Psychiatric Institute, New York, USA.
Stephanie BrazisNew York State Psychiatric Institute, New York, USA.
Megan R MayerNew York State Psychiatric Institute, New York, USA.
Marlene CarlsonNew York State Psychiatric Institute, New York, USA.
Joshua T KantrowitzNew York State Psychiatric Institute, New York, USA.ORCID 0000-0003-1127-7016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith numerous potentially novel targets and pharmacodynamic biomarkers for schizophrenia entering late-stage testing, the next decade will bring an urgent need for well-conducted clinical trials. A critically important step for the successful execution of clinical research trials is timely and appropriate recruitment of participants. Patients with schizophrenia can be especially challenging to recruit because of the disability inherent in psychotic spectrum disorders. Research on how best to recruit for clinical trials is understudied. Clearly defining a model for recruitment procedures would be valuable for researchers and, by extension, the patient populations that may benefit from the insight gained by future clinical research.

methodsThis article aims to offer suggestions for recruitment based on years of experience at the Columbia Schizophrenia Research Clinic (CSRC), a hub for clinical trials focusing on the etiology and treatment of various psychotic disorders.

resultsThe present report provides practical, step-by-step recommendations for implementing the highly effective CSRC recruitment model, including the benefits of 2 recruitment initiatives that were instituted in 2018: hiring a dedicated recruiter and targeted chart reviews at affiliated clinics. Other topics discussed include our umbrella protocol and database, advertising, and tips for collaborating with external sites.

conclusionsDespite ongoing complications from coronavirus disease 2019, these strategies have been successful, increasing the rate of both consents and study enrollments by approximately 40% and enabling the CSRC to conduct multiple studies simultaneously.

Indexed as

COVID-19Psychotic DisordersSchizophreniaHumansLongitudinal StudiesPatient SelectionChallengesrecruitmentresearchschizophreniastrategies

Identifiers

PMID36037521
PMCPMC9452184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.